Oral administration of genetically modified Bifidobacterium displaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice.

Highlights: [•] We generated recombinant bifidobacterium displaying HCV-NS3 as an oral vaccine. [•] The oral administration of this vaccine induced the NS3-specific immunity in mice. [•] This vaccine could be a novel therapeutic vaccine against chronic HCV infection. [Copyright &y& Elsevier]